Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502059 | 0.73 | RHEB (0.48) | RHEB | |
| SCHEMBL6000210 | 0.72 | SLC6A4 (0.56) | RHEBSLC6A4 | |
| SCHEMBL6000215 | 0.71 | RHEB (0.46) | RHEBSLC6A4 | |
| SCHEMBL7670453 | 0.66 | HTR2A (0.47) | — | |
| SCHEMBL7583374 | 0.66 | TP53 (0.41) | — | |
| SCHEMBL5999543 | 0.66 | PDE7A (0.43) | SLC6A4 | |
| SCHEMBL20536492 | 0.65 | RHEB (1.00) | RHEB | |
| SCHEMBL1013714 | 0.64 | NR3C1 (0.40) | RHEB | |
| SCHEMBL7207553 | 0.62 | GPR84 (0.41) | RHEB | |
| SCHEMBL20535781 | 0.62 | RHEB (1.00) | RHEBSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | RHEB 2914/4885SLC6A4 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.